HEARD hosts high level discussion on ‘The future of AIDS financing in Africa.’
HEARD recently hosted a unique meeting of African ministers of Health at the Ditchley Foundation, Oxford, in the UK. Also in attendance were selected Directors of National AIDS Commissions, UNAIDS officials, the World Bank, United Nations Development Programme, Swedish International Development Cooperation and other concerned organisations to consider the future of AIDS financing. The meeting was organised by Professor Nana K. Poku, Health Economics Research Chair at the UKZN. The discussions turned on the call by UNAIDS for greatly increased funding in order to meet its accelerated ‘Fast Track’ for the five years to 2020 – and beyond that, to the 2030 Sustainable Development Goals (SDGs).
Discussions focused on two fundamental tensions.
The first, being that HIV and AIDS are now sited within the very large and encompassing SDG, which cover nearly every important aspect of human security and environmental stability. The cost implications of any combination of the larger of these issues (climate change; ending poverty in all its form) will sharpen the unavoidable political differences over prioritisation. The second of these tensions being the imperative of establishing or greatly extending and improving Universal Health Coverage (UHC) in southern African countries, while consolidating and furthering the advances made against AIDS to date.
There is very considerable inertia behind the massive and costly roll-out of anti-retroviral treatment (ART) to 18 million individuals, which include the burdens entailed in keeping these regimes in place into succeeding decades. In addition, as many as twenty-six million HIV-positive people await treatment availability; and a ‘test and treat’ approach has been advocated by UNAIDS. Yet, despite the changed and changing fiscal landscape, a ‘more of the same, but better’ ethos persists – and with it, not a grounded reconsideration of ends and means, but a hope that African states will be able to ‘create fiscal space’ and find efficiencies on a scale that will not only cover donor shortfalls but will also secure a near-doubling on resources.
Historically, we know that the steepest declines in new HIV infections have arisen from behavioral change, but identifying what is most effective has proved difficult to identify and is very likely to be highly context-dependent. This makes more research into effective and enduring behavioral change for the purpose of reducing infections a first-order priority. Also evident in the discussions was a divergence over the how the struggle against AIDS should relate to the progression of UHC. Although arguments which turn on ‘vertical versus horizontal’ approaches are over-simplifications, so too are the ideas that (where it exists), complementarity between AIDS and primary health services can obviate the need for hard choices, or that the negative and disruptive legacies of AIDS provision in matters ranging from sustainability to staff shortages can quickly be surmounted. Nor can the AIDS funding crunch be abstracted from the political and legal responsibilities of Health Ministries, the worsening problem of non-communicable diseases, or normative expectation (both local and international) for something which at least approaches the ideal of universal health.
The era of AIDS primacy and abundant resources is already over, but we have not yet adjusted our strategic thinking—and now, more than one year into the five-year ‘Fast Track ‘ period, we have no time to lose. Instead of insisting on and hoping for the ideal, we must calculate how much we can accomplish with considerably less. Hard choices await, but failure to recognise that ‘business as usual’ is not an option will make those choices harder still.
HEARD recently hosted the second in a series of high-level retreats around domestic financing and prioritisation of health under the United Nations Sustainable Development Goals, better known as SDGs. The meeting took place at the Thanda Private Game Reserve in Hluhluwe, South Africa between 28 ...>>
December 1 marked World AIDS Day. A brief moment reflection our recent achievements in the fight against HIV and AIDS point to some significant victories. Globally, we have more scientific knowledge on how the virus is transmitted with prevention and treatment options being tailored to suit ...>>
Media release: HEARD embarks on an extensive research project on young key populations in SADC countries
HEARD embarks on an extensive research project on young key populations in SADC countries, in collaboration with the United Nations Development Programme and African Men for Sexual Health and Rights Durban, South Africa | 1 December 2016 HEARD has successfully obtained a large research grant to ...>>
HEARD’s Scholarship Programme aims to emphasise the mastery of quantitative and qualitative methods for understanding policy problems and for devising, evaluating and/or implementing policy solutions. The aim of providing PhD scholarships is to produce expertly qualified graduates to advise or ...>>
Economics, financing and HIV: Reflections from the 2016 International AIDS Economics Network Preconference
[Original post on Results for Development ] Last month’s International AIDS Economics Network (IAEN) Preconference in Durban (July 15-16, 2016) demonstrated the strong political will to prioritize financing and harness economics to sustain the global HIV response and end AIDS. What a long way ...>>
It is now possible for antiretroviral therapy (ART) to reduce viral load of HIV to the point where an infected person is no longer, or much less, infectious to others. As a result, ‘treatment as prevention’ has become the cornerstone of UNAIDS’s post-2015 global strategy to end AIDS by 2030. As ...>>
Prof Nana Poku | HEARD’s Executive Director The UNAIDS Fast-Tracking to Zero Strategy is on its own a large and rightly ambitious undertaking, building on the success of the fifteen-year span of the Millennium Development Goals (MDG). MDG 6 was closely related to, and broadly consonant ...>>
We have recently seen a spurt of advances in biomedical HIV prevention research. These interventions include circumcision, vaccines, microbicides, pre-exposure prophylaxis and suppressive therapy for herpes simplex virus-2 (HSV-2) to reduce risks of HIV transmission through sexual intercourse. ...>>